Internal Reference Number: FOI_7723
Date Request Received: 02/02/2024 00:00:00
Date Request Replied To: 23/02/2024 00:00:00
This response was sent via: By Email
Request Summary: new biologic and targeted medications within dermatology and respiratory medicine
Request Category: Companies
| Question Number 1: How many patients were treated in January 2024 (or latest available month) by the Dermatology department with the following drugs: • Abrocitinib (Cibinqo) • Baricitinib (Olumiant) • Dupilumab (Dupixent) • Lebrikizumab (Ebglyss) • Omalizumab (Xolair) • Tralokinumab (Adtralza) • Upadacitinib (Rinvoq) | |
| Answer To Question 1: Please see below data for dermatology patients treated in January: • Abrocitinib (Cibinqo) - Not used at SFT • Baricitinib (Olumiant) - <5 • Dupilumab (Dupixent) - 7 • Lebrikizumab (Ebglyss) - Not used at SFT • Omalizumab (Xolair) - 6 • Tralokinumab (Adtralza) - <5 • Upadacitinib (Rinvoq) - <5 | |
| Question Number 2: How many patients were treated in January 2024 (or latest available month) by the Respiratory Medicine department with the following drugs: • Benralizumab (Fasenra) • Dupilumab (Dupixent) • Mepolizumab (Nucala) • Omalizumab (Xolair) • Reslizumab (Cinqaero) • Tezepelumab (Tezspire) | |
| Answer To Question 2: • Benralizumab (Fasenra) - 0 • Dupilumab (Dupixent) <5 • Mepolizumab (Nucala) 0 • Omalizumab (Xolair) 6 • Reslizumab (Cinqaero) 0 • Tezepelumab (Tezspire) 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
